Clinical trials: Thromboembolic Disease Recurrent, open to volunteers
Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis
Apixaban in Thrombocytopenia
This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis, Thrombocytopenia, Recurrent Venous Thromboembolism
- Trial name
- NCT06886516
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rushad Patell
Cerebral Venous Thrombosis
Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam
This prospective, single-arm observational cohort study aims to evaluate the real-world effectiveness and safety of direct oral anticoagulants (DOACs), specifically dabigatran or rivaroxaban, in patients with cerebral venous…
- Trial name
- DCVT-VN25 (NCT07083609)
- Testing
- Dabigatran, Rivaroxaban
- Where
- Vietnam
- Volunteers
- 69 people
- Sponsor
- Hieu Trung Dinh
Venous Thromboembolic Disease
Cohort for Monitoring Patients With Venous Thromboembolic Disease
Venous thromboembolic disease is a common pathology in the general population (1.5/1000), the prognosis of which depends in particular on the risk of recurrence.
- Trial name
- CoMTEV (NCT07016542)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Rouen
Thromboembolic Venous Disease
Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence
The main objective of the BREIZH-Cohorte study is to determine the incidence of recurrent short, medium and long-term thromboembolic venous disease as well as risk factors for recurrence in two specific populations: patients…
- Trial name
- BREIZH-Cohorte (NCT04297085)
- Testing
- Biologic sample
- Where
- 4 sites in France
- Volunteers
- 3,400 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism, Anticoagulant
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal…
- Conditions
- Venous Thromboembolism, Anticoagulant, Elderly
- Trial name
- Jason (NCT04257487)
- Testing
- Sulodexide
- Where
- Italy
- Volunteers
- 1,455 people
- Sponsor
- Arianna Anticoagulazione Foundation
Percutaneous Left Atrial Appendage Occlusion (LAAO), Device-related Thrombus (DRT)
Recurrent or Persistent Device Related Thrombus After Left Atrial Appendage Occlusion: The RE-DRT Study
This study is a prospective, multicenter international trial aimed at assessing the actual incidence, identifying associated factors, and evaluating the clinical consequences of both persistent and recurrent device-related…
- Conditions
- Percutaneous Left Atrial Appendage Occlusion (LAAO), Device-related Thrombus (DRT), Thromboembolic Event, Major Cardioembolic Events
- Trial name
- RE-DRT (NCT06177704)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Atrial Fibrillation (AF)
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF).
- Trial name
- DESTINATION (NCT06615596)
- Testing
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Where
- 12 sites in United States, China
- Volunteers
- 3,160 people
- Sponsor
- China National Center for Cardiovascular Diseases
Cancer-associated Thrombosis
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism…
- Trial name
- CAN-CATCH (NCT06894576)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Ottawa Hospital Research Institute